Megestrol acetate
Megace, Megestrol (megestrol acetate) is a small molecule pharmaceutical. Megestrol acetate was first approved as Megace on 1982-01-01. It is used to treat anorexia, breast neoplasms, cachexia, and endometrial neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Megace (generic drugs available since 1988-08-08)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03A: Hormonal contraceptives for systemic use
— G03AA: Progestogens and estrogen systemic contraceptives, fixed combinations
— G03AA04: Megestrol and ethinylestradiol
— G03AB: Progestogens and estrogens systemic contraceptives, sequential preparations
— G03AB01: Megestrol and ethinylestradiol
— G03AC: Progestogen systemic hormonal contraceptives
— G03AC05: Megestrol
— G03D: Progestogen sex hormones and modulators of the genital system
— G03DB: Pregnadien derivatives, progestogens
— G03DB02: Megestrol
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA08: Megestrol and estrogen
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB04: Megestrol and estrogen
L: Antineoplastic and immunomodulating agents
— L02: Endocrine therapy antineoplastic and immunomodulating agents
— L02A: Hormones and related agents
— L02AB: Progestogens, endocrine therapy drugs
— L02AB01: Megestrol
HCPCS
Code | Description |
|---|---|
| S0179 | Megestrol acetate, oral, 20 mg |
Clinical
Clinical Trials
89 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anorexia | D000855 | HP_0002039 | R63.0 | 1 | 7 | 8 | 1 | — | 16 |
| Cachexia | D002100 | HP_0004326 | R64 | 2 | 4 | 6 | 2 | — | 14 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | 1 | 1 | 2 | 8 |
| Second primary neoplasms | D016609 | — | — | — | — | — | 1 | — | 1 |
| Feeding behavior | D005247 | — | — | — | — | — | 1 | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 3 | 16 | 4 | — | 1 | 20 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | 11 | 7 | — | — | 12 |
| Neoplasms | D009369 | — | C80 | — | 4 | 2 | — | 1 | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | 2 | — | — | 7 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | 1 | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | 1 | 2 |
| Body weight changes | D001836 | — | — | — | 1 | 1 | — | — | 2 |
| Weight loss | D015431 | HP_0001824 | — | — | — | 2 | — | — | 2 |
| Overweight | D050177 | — | E66.3 | — | 2 | 2 | — | — | 2 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv wasting syndrome | D019247 | EFO_0007312 | — | 1 | 2 | — | — | 1 | 4 |
| Endometrioid carcinoma | D018269 | — | — | 1 | 3 | — | — | — | 3 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
| Phenylketonurias | D010661 | — | E70.0 | — | 1 | — | — | — | 1 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | — | — | — | — | — | — | 1 | 1 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Fertility preservation | D059247 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Megestrol acetate |
| INN | megestrol |
| Description | Megestrol acetate is a steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. It has a role as an antineoplastic agent, an appetite enhancer, a contraceptive drug, a progestin and a synthetic oral contraceptive. It is a steroid ester, an acetate ester, a 20-oxo steroid and a 3-oxo-Delta(4) steroid. It is functionally related to a megestrol. |
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 595-33-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201139 |
| ChEBI ID | — |
| PubChem CID | 11683 |
| DrugBank | DB00351 |
| UNII ID | EA6LD1M70M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Megestrol acetate
+
Megestrol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,311 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,894 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use